HHS launches AI initiative to accelerate clinical trials, counter China's research pace

HHS announced new efforts to use AI to speed up and expand clinical trials, explicitly framed as a competitive response to China's faster clinical research. The initiative signals a policy shift toward AI-enabled trial design and execution, though specific mechanisms and funding remain unspecified. This matters as it could reshape drug development timelines and US competitiveness in biomedical innovation.